Hadassah

Israeli Biotech Co. Receives Major Grant to Further Develop Treatment for AMD

Wednesday, May 13 2015

To further develop its world-first, animal product-free stem cell treatment for age-related macular degeneration (AMD), Israel’s Cell Cure Neurosciences Ltd. has received a 6.24 million shekel (approximately $1.6 million dollar) grant from Israel's Office of the Chief Scientist (OCS).

A clinical trial using this product was initiated in February at the Hadassah Medical Organization, whose Prof. Benjamin Reubinoff, Chief Scientific Officer of Cell Cure and Director of Hadassah's Human Embryonic Stem Cell Research Center, and Prof. Eyal Banin, head of the Center for Retinal and Macular Degeneration, were instrumental in its development. The product, called OpRegen®, is a retinal pigment epithelial (RPE) cell formulation derived from human embryonic stem cells (hESCs), characterized by high purity and potency.

"We thank the Israel Office of the Chief Scientist for its commitment to innovation and for continuing support of Cell Cure and its development of a cell therapy-based treatment for a major disease of aging," said Charles Irving, PhD, Chief Executive Officer of Cell Cure.

"I join with Dr. Irving in thanking the OCS for its generous support in advancing pluripotent stem cell research into clinical applications," Prof. Reubinoff related.

The Phase I/IIa study of OpRegen® has been designed to provide preliminary, objective, functional and structural data on this cell transplantation's ability to slow the progression of geographic atrophy (dry-AMD), in addition to safety data. Dry-AMD severely impacts the quality of life of the elderly and there is as yet no approved therapy.

The clinical trial, involving four groups of patients, will evaluate three different dose regimens. Cell Cure expects to report interim data from the cohorts in the coming months. Details of the trial are available at https://clinicaltrials.gov/ct2/show/NCT02286089?term=OpRegen&rank=1

Dry AMD is the leading cause of visual impairment and blindness among the elderly in the US and other developed countries. While treatment options exist for the treatment of the wet form of AMD, 90 percent of all patients with AMD have the dry form. As Cell Cure's website explains: "The root cause of dry-AMD is believed to be the dysfunction of RPE cells. Therefore, one of the most exciting new therapeutic strategies for dry-AMD is the transplantation of healthy young RPE cells to support and replace those lost with age. Pluripotent stem cells, such as hESCs, can potentially provide a means of manufacturing such healthy RPE cells on an industrial scale."

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Tuesday, Nov 14 2017

Abraham and Sarah — and a Modern-Day Miracle Baby

They're not quite Matriarch Sarah and Patriarch Abraham, who were 90 and 100, respectively, when their son, Isaac, was born. This couple--she’s 48 and he is 62--are parents of a baby boy, thanks to a hand from heaven and the team at Hadassah Hospital Mount Scopus.

READ MORE ›
alt_text

Thursday, Nov 9 2017

New NICU at Hadassah: First of Its Kind in Israel

Tiny patients with big problems are now being treated in the new Neonatal Intensive Care Unit (NICU) at Hadassah Hospital Ein Kerem—the first of its kind in Israel.

READ MORE ›
alt_text

Monday, Oct 30 2017

Hadassah Hospital Metrics on the Rise

HMO By The Numbers

READ MORE ›
alt_text

Tuesday, Oct 24 2017

Hadassah Doctor Brings New Hope to Cystic Fibrosis Patients

Twenty five years ago, Dr. Batsheva Kerem and Dr. Eitan Kerem made a significant contribution to the scientific world’s understanding of genetic mutations and cystic fibrosis.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More